<DOC>
	<DOC>NCT03054402</DOC>
	<brief_summary>This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics and explore the pharmacodynamics of ascending single doses of BAY1834845 using a placebo controlled, randomized, single center design.</brief_summary>
	<brief_title>First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<criteria>Healthy male subject Age: 18 to 50 years (inclusive) at the first screening visit Body mass index (BMI) : 18.5 ≤ BMI ≤ 30 kg/m² Clinically relevant findings in the physical examination Relevant diseases within the last 4 weeks prior to the first study drug administration Incompletely cured preexisting diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal Use of systemic or topical medicines or substances which oppose the study objectives or which might influence them within 4 weeks before first study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>